Media-OutReach Newswire Fosun’s Core Businesses Grow Significantly, Nomura Reiterates "Overweight" Rating
2023 VinFuture Special Prize Laureate Prof. Daniel Drucker: Ample room remains for innovation in GLP-1 therapies 2.
Bora Pharmaceuticals Exits Integration Phase with Sequentially-Improved Gross and Operating Margins 5.